adx10059
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00820079)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Metabotropic glutamate receptor 5MODULATOR
GRM5 modulator
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C)c(N)c(C#Cc2cccc(F)c2)n1- Mol. weight
- 240.28 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545036 ↗
Also known as
- adx10059
- adx10059
- adx-10059
- adx-10059
- raseglurant
- raseglurant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00810485 | Phase 2 | Dec 1, 2008 | Addex Pharma |
| NCT00820079 | Phase 2 | Dec 1, 2008 | Addex Pharma |
| NCT00820105 | Phase 2 | Dec 1, 2008 | Addex Pharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Addex Pharma | For profit | 3 | 3 | 1 | 2008 |
1 organizations
Page 1 / 1